Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has received a non-dilutive grant from the Department of Defense to further its groundbreaking lung cancer biomarker research. This strategic funding supports the company's ongoing development of ENV105, an experimental antibody targeting CD105, a protein identified as a key driver of cancer treatment resistance.
The research focuses on understanding and potentially reversing mechanisms that enable cancer cells to develop resistance to standard therapies. By targeting CD105, Kairos aims to restore the effectiveness of existing cancer treatments across multiple cancer types, with particular emphasis on prostate and non-small cell lung cancers.
Currently, Kairos is advancing two critical clinical trials for ENV105. A Phase 2 trial is underway for castrate-resistant prostate cancer, while a Phase 1 trial is exploring potential applications in lung cancer. The company anticipates releasing safety and interim efficacy results in the second quarter of 2025, which could represent a significant milestone in oncological research.
The Department of Defense grant represents more than financial support; it validates the potential scientific importance of Kairos's research approach. By providing non-dilutive funding, the government agency demonstrates confidence in the company's innovative strategy to address drug resistance, a persistent challenge in cancer treatment.
In addition to ENV105, Kairos is developing KROS101, an immune response modulator that has already generated interest through presentations at key oncology conferences. The company's robust intellectual property portfolio, extending into the 2030s, positions it favorably in the competitive biopharmaceutical landscape.
The research has broader implications for cancer treatment. Drug resistance remains a significant obstacle in effectively managing various cancer types, often leading to treatment failure and disease relapse. By targeting CD105, which elevates in response to standard therapies, Kairos's approach could potentially create new pathways for more consistent and effective cancer interventions.
With ongoing support from financial analysts at firms like EF Hutton and HC Wainwright, and strategic government funding, Kairos Pharma is poised to make meaningful contributions to understanding and potentially overcoming cancer treatment challenges.
